Nkarta Announces Key Senior Leadership Team Appointments
25 Julio 2022 - 3:31PM
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical
company developing engineered natural killer (NK) cell therapies to
treat cancer, today announced the promotions of Ralph
Brandenberger, PhD, to Chief Technical Officer and Yvonne Li, MBA,
to Chief Administrative Officer.
“Ralph and Yvonne have each distinguished
themselves through their exceptional accomplishments, leadership of
collaborative teams and valuable cross-functional contributions to
Nkarta,” said Paul J. Hastings, President and CEO of Nkarta. “As
Nkarta enters its next stage of growth in preparing for potential
future commercialization, their continued leadership will be
central to scaling and delivering off-the-shell NK cell therapies
for patients.”
Dr. Brandenberger oversees technical operations,
including process and analytical development, supply chain,
manufacturing, and quality for Nkarta’s engineered NK cell therapy
candidates. He has more than 20 years of experience in process and
analytical development and biopharmaceutical manufacturing with
deep experience in end-to-end technical operations and the
successful scale-up of complex cell therapy agents. Dr.
Brandenberger joined Nkarta in April 2018 and most recently served
as Senior Vice President, Technical Operations. Prior to joining
Nkarta, he held leadership roles in process development, technical
operations and manufacturing of cellular therapeutics at Neurona
Therapeutics, Baxter Healthcare, and Geron Corp.
Dr. Brandenberger started his scientific career at Celera
Genomics. He received his MS in biology and PhD in cell biology
from the Biocenter, University of Basel, Switzerland and completed
postdoctoral training at the Howard Hughes Medical Institute at the
University of California, San Francisco.
Ms. Li oversees Nkarta’s accounting
organization, and associated budgetary and administrative
operations, financial and regulatory compliance, and human
resources administration. She has nearly 25 years of experience in
corporate finance and accounting. Ms. Li joined Nkarta in November
2019 as Senior Vice President, Finance to lead the company’s
financial management, treasury, tax, accounting, and SEC reporting
operations. Prior to joining Nkarta, she held senior leadership
roles in finance, accounting and operations at Amunix and OncoMed.
Ms. Li is a Certified Public Accountant (inactive) and member of
the American Institute of Certified Public Accountants. She earned
her BA from the National Taiwan Normal University and MBA from San
Francisco State University.
About Nkarta Nkarta is a
clinical-stage biotechnology company advancing the development of
allogeneic, off-the-shelf natural killer (NK) cell therapies for
cancer patients. By combining its cell expansion and
cryopreservation platform with proprietary cell engineering
technologies and CRISPR-based genome engineering capabilities,
Nkarta is building a pipeline of future cell therapies engineered
for deep anti-tumor activity and intended for broad access in the
outpatient treatment setting. For more information, please visit
the company’s website at www.nkartatx.com.
Cautionary Note on Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
"anticipates," "believes," "expects," "intends," “plans,”
“potential,” "projects,” “would,” and "future" or similar
expressions are intended to identify forward-looking statements.
Examples of these forward-looking statements include statements
concerning Nkarta’s expectations regarding any or all of the
following: the future commercialization of Nkarta’s product
candidates; Nkarta’s ability to scale and deliver off-the-shelf NK
cell therapies; and the potential impact of changes in Nkarta’s
leadership.
Because forward looking statements are subject
to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
These risks and uncertainties include, among others: Nkarta’s
limited operating history and historical losses; Nkarta’s lack of
any products approved for sale and its ability to achieve
profitability; the risk that the results of preclinical studies and
early-stage clinical trials may not be predictive of future
results; Nkarta’s ability to raise additional funding to complete
the development and any commercialization of its product
candidates; Nkarta’s dependence on the success of its co-lead
product candidates, NKX101 and NKX019; that Nkarta may be delayed
in initiating, enrolling or completing any clinical trials;
competition from third parties that are developing products for
similar uses; Nkarta’s ability to obtain, maintain and protect its
intellectual property; Nkarta’s dependence on third parties in
connection with manufacturing, clinical trials, and pre-clinical
studies; the complexity of the manufacturing process for CAR NK
cell therapies; and risks relating to the impact on Nkarta’s
business of the COVID-19 pandemic or similar public health
crises.
These and other risks are described more fully
in Nkarta’s filings with the Securities and Exchange Commission
(“SEC”), including the “Risk Factors” section of Nkarta’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2022, filed
with the SEC on May 12, 2022, and Nkarta’s other documents
subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Nkarta undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Nkarta Media/Investor
ContactGreg MannNkarta, Inc.gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024